Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Transcutaneous Determination of Tissue Dihematoporphyrin Ether Content: A Device to Optimize Photodynamic Therapy

Transcutaneous Determination of Tissue Dihematoporphyrin Ether Content: A Device to Optimize... Abstract • Photodynamic therapy involves the use of light of appropriate wavelength to excite a photosensitizer resulting in tissue destruction. The photosensitizer dihematoporphyrin ether is selectively retained in tumors allowing for tumor destruction while sparing normal structures. Accessibility of skin tumors makes them well suited for photodynamic therapy. Tissue and tumor dihematoporphyrin ether content is estimated based on the amount of dihematoporphyrin ether administered. In our study, skin dihematoporphyrin ether content was measured in guinea pigs transcutaneously by a hand-held fluorometer and compared with dihematoporphyrin ether determinations done on skin biopsy specimens. Fluorometry was performed on guinea pigs receiving 0,2.5,5, 10, and 25 mg/kg of dihematoporphyrin ether. Transcutaneous measurements of skin fluorescence increased with increasing dihematoporphyrin ether dose and correlated well with skin dihematoporphyrin ether content as determined by extracting dihematoporphyrin ether from skin samples. Transcutaneous fluorescent measurements of guinea pigs given 0 and 2.5, 2.5 and 5, 5 and 10, and 10 and 25 mg/kg of dihematoporphyrin ether differed in a statistically significant manner. Transcutaneous fluorometric determination of dihematoporphyrin ether content and extraction of dihematoporphyrin ether from skin samples were able to reflect differences in dihematoporphyrin ether dosing and presumably skin dihematoporphyrin ether content. However, transcutaneous fluorometry provides an instantaneous estimate of tissue dihematoporphyrin ether without the need for a tissue sample. This may provide a clinical tool to predict more accurately the optimal light dose necessary to maximize photodynamic therapy. References 1. Mitchell JB, McPherson S, DeGraff W, Gamson J, Zabell A, Russo A. Oxygen dependence of hematoporphyrin-induced photoactivation of Chinese hamster cells . Cancer Res . 1985;45:2008-2011. 2. Moan J, Sommer S. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells . Cancer Res . 1985;45:1608-1610. 3. Russo AR, Mitchell JB, Pass HI, Glatstein EJ. Photodynamic therapy . In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer . Principles and Practice of Oncology . Philadelphia, Pa: JB Lippincott; 1989:2449-2459. 4. Dougherty TJ. Photosensitizers: therapy and detection of malignant tumors . Photochem Photobiol . 1987;45:879-889.Crossref 5. Kennedy J. HPD photoradiation therapy for cancer at Kingston and Hamilton . In: Kessel D, Dougherty TJ, eds. Porphyrin Photosensitization . New York, NY: Plenum Press; 1983:53-62. 6. Kennedy JC, Oswald K. Hematoporphyrin derivative photoradiation therapy in theory and practice . In: Andrioni A, Cubedda R, eds. Porphyrins in Tumor Phototherapy . New York, NY: Plenum Press; 1983:365. 7. Zorat PL, Romio L, Corti L, et al. Hematoporphyrin phototherapy of malignant tumors . In: Andreoni A, Cubedda R, eds. Porphyrins in Tumor Phototherapy . New York, NY: Plenum Press; 1983:381. 8. Berns MW, Wile AG. Hematoporphyrin phototherapy of cancer . Radiother Oncol . 1986;7:233-240.Crossref 9. Bernstein EF, Thomas GF, Smith PD, et al. Response of black and white guinea pig skin to photodynamic treatment using 514-nm light and dihematoporphyrin ether . Arch Dermatol . 1990;126:1303-1307.Crossref 10. Nelson JS, McCullough JL, Berns MW. Photodynamic therapy of human malignant melanoma xenografts in athymic nude mice . J Natl Cancer Inst . 1988;80:56-60.Crossref 11. Gomer CJ, Jester JV, Razum NJ, Szirth BC, Murphree AL. Photodynamic therapy of intraocular tumors examination of hematoporphyrin derivative distribution and long-term damage in rabbit ocular tissue . Cancer Res . 1985;45:3718-3725. 12. McCullough JL, Weinstein GD, Douglas JL, Berns MW. Photosensitizers in dermatology . Photochem Photobiol . 1987;46:77-82.Crossref 13. Bandieramonte G, Marchesini R, Melloni, E et al. Laser phototherapy following HpD administration in superficial neoplastic lesions . Tumori . 1984;70:327-334. 14. Lange K, Krewer SE. The dermofluorometer . J Lab Clin Med . 1943;28:1746-1750. 15. Silverman DG, LaRosa DD, Barlow CH, Bering TG, Popky LM, Smith TC. Quantification of tissue fluorescein delivery and prediction of flap viability with the fiberoptic dermofluorometer Plast Reconstr Surg . 1980;66:545-553.Crossref 16. Silverman DG, Weinstock BS, Brousseau DA, Norton KJ, Kniffin SA, Smtih G. Comparative assessment of blood flow to canine island flaps . Arch Otolaryngol Head Neck Surg . 1985;111:677-681.Crossref 17. Ostrander LE, Lee BY, Silverman DA, Groskopf RA. Constant infusion fluorometry to predict flap survival . Decubitus 1989;2:40-46. 18. Burnham SJ, Wagner WH, Keagy BA, Johnson G Jr. Objective measurement of limb perfusion by dermal fluorometry . Arct Surg . 1990;125:104-106.Crossref 19. Chowdary RP, Campbell SP, Rosenberg M, Hugo NE. Dermofluorometric prediction of flap survival . Ann Plast Surg . 1987;19:154-157.Crossref 20. Thomson JG, Kerrigan CL. Dermofluorometry: thresholds for predicting flap survival . Plast Reconstr Surg . 1989;83:859-863.Crossref 21. Weinberg H, Pozez A. Comparison of skin surface fluorescence and fluorescein tissue concentration with the dermofluorometer . Microsurgery . 1988;9:24-7.Crossref 22. Moore JV, Keene JP, Land EJ. Dose-response relationships for photodynamic injury to murine skin . Br J Radiol . 1986;59:257-261.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Transcutaneous Determination of Tissue Dihematoporphyrin Ether Content: A Device to Optimize Photodynamic Therapy

Download PDF
5 pages

Loading next page...
 
/lp/american-medical-association/transcutaneous-determination-of-tissue-dihematoporphyrin-ether-content-wHMMfUpokq

References (24)

Publisher
American Medical Association
Copyright
Copyright © 1991 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1991.04520010040004
Publisher site
See Article on Publisher Site

Abstract

Abstract • Photodynamic therapy involves the use of light of appropriate wavelength to excite a photosensitizer resulting in tissue destruction. The photosensitizer dihematoporphyrin ether is selectively retained in tumors allowing for tumor destruction while sparing normal structures. Accessibility of skin tumors makes them well suited for photodynamic therapy. Tissue and tumor dihematoporphyrin ether content is estimated based on the amount of dihematoporphyrin ether administered. In our study, skin dihematoporphyrin ether content was measured in guinea pigs transcutaneously by a hand-held fluorometer and compared with dihematoporphyrin ether determinations done on skin biopsy specimens. Fluorometry was performed on guinea pigs receiving 0,2.5,5, 10, and 25 mg/kg of dihematoporphyrin ether. Transcutaneous measurements of skin fluorescence increased with increasing dihematoporphyrin ether dose and correlated well with skin dihematoporphyrin ether content as determined by extracting dihematoporphyrin ether from skin samples. Transcutaneous fluorescent measurements of guinea pigs given 0 and 2.5, 2.5 and 5, 5 and 10, and 10 and 25 mg/kg of dihematoporphyrin ether differed in a statistically significant manner. Transcutaneous fluorometric determination of dihematoporphyrin ether content and extraction of dihematoporphyrin ether from skin samples were able to reflect differences in dihematoporphyrin ether dosing and presumably skin dihematoporphyrin ether content. However, transcutaneous fluorometry provides an instantaneous estimate of tissue dihematoporphyrin ether without the need for a tissue sample. This may provide a clinical tool to predict more accurately the optimal light dose necessary to maximize photodynamic therapy. References 1. Mitchell JB, McPherson S, DeGraff W, Gamson J, Zabell A, Russo A. Oxygen dependence of hematoporphyrin-induced photoactivation of Chinese hamster cells . Cancer Res . 1985;45:2008-2011. 2. Moan J, Sommer S. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells . Cancer Res . 1985;45:1608-1610. 3. Russo AR, Mitchell JB, Pass HI, Glatstein EJ. Photodynamic therapy . In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer . Principles and Practice of Oncology . Philadelphia, Pa: JB Lippincott; 1989:2449-2459. 4. Dougherty TJ. Photosensitizers: therapy and detection of malignant tumors . Photochem Photobiol . 1987;45:879-889.Crossref 5. Kennedy J. HPD photoradiation therapy for cancer at Kingston and Hamilton . In: Kessel D, Dougherty TJ, eds. Porphyrin Photosensitization . New York, NY: Plenum Press; 1983:53-62. 6. Kennedy JC, Oswald K. Hematoporphyrin derivative photoradiation therapy in theory and practice . In: Andrioni A, Cubedda R, eds. Porphyrins in Tumor Phototherapy . New York, NY: Plenum Press; 1983:365. 7. Zorat PL, Romio L, Corti L, et al. Hematoporphyrin phototherapy of malignant tumors . In: Andreoni A, Cubedda R, eds. Porphyrins in Tumor Phototherapy . New York, NY: Plenum Press; 1983:381. 8. Berns MW, Wile AG. Hematoporphyrin phototherapy of cancer . Radiother Oncol . 1986;7:233-240.Crossref 9. Bernstein EF, Thomas GF, Smith PD, et al. Response of black and white guinea pig skin to photodynamic treatment using 514-nm light and dihematoporphyrin ether . Arch Dermatol . 1990;126:1303-1307.Crossref 10. Nelson JS, McCullough JL, Berns MW. Photodynamic therapy of human malignant melanoma xenografts in athymic nude mice . J Natl Cancer Inst . 1988;80:56-60.Crossref 11. Gomer CJ, Jester JV, Razum NJ, Szirth BC, Murphree AL. Photodynamic therapy of intraocular tumors examination of hematoporphyrin derivative distribution and long-term damage in rabbit ocular tissue . Cancer Res . 1985;45:3718-3725. 12. McCullough JL, Weinstein GD, Douglas JL, Berns MW. Photosensitizers in dermatology . Photochem Photobiol . 1987;46:77-82.Crossref 13. Bandieramonte G, Marchesini R, Melloni, E et al. Laser phototherapy following HpD administration in superficial neoplastic lesions . Tumori . 1984;70:327-334. 14. Lange K, Krewer SE. The dermofluorometer . J Lab Clin Med . 1943;28:1746-1750. 15. Silverman DG, LaRosa DD, Barlow CH, Bering TG, Popky LM, Smith TC. Quantification of tissue fluorescein delivery and prediction of flap viability with the fiberoptic dermofluorometer Plast Reconstr Surg . 1980;66:545-553.Crossref 16. Silverman DG, Weinstock BS, Brousseau DA, Norton KJ, Kniffin SA, Smtih G. Comparative assessment of blood flow to canine island flaps . Arch Otolaryngol Head Neck Surg . 1985;111:677-681.Crossref 17. Ostrander LE, Lee BY, Silverman DA, Groskopf RA. Constant infusion fluorometry to predict flap survival . Decubitus 1989;2:40-46. 18. Burnham SJ, Wagner WH, Keagy BA, Johnson G Jr. Objective measurement of limb perfusion by dermal fluorometry . Arct Surg . 1990;125:104-106.Crossref 19. Chowdary RP, Campbell SP, Rosenberg M, Hugo NE. Dermofluorometric prediction of flap survival . Ann Plast Surg . 1987;19:154-157.Crossref 20. Thomson JG, Kerrigan CL. Dermofluorometry: thresholds for predicting flap survival . Plast Reconstr Surg . 1989;83:859-863.Crossref 21. Weinberg H, Pozez A. Comparison of skin surface fluorescence and fluorescein tissue concentration with the dermofluorometer . Microsurgery . 1988;9:24-7.Crossref 22. Moore JV, Keene JP, Land EJ. Dose-response relationships for photodynamic injury to murine skin . Br J Radiol . 1986;59:257-261.Crossref

Journal

Archives of Dermatology – American Medical Association

Published: Dec 1, 1991

There are no references for this article.